肝癌切除术辅以DC―CIK细胞治疗原发性肝癌安全性及可行性分析.docVIP

肝癌切除术辅以DC―CIK细胞治疗原发性肝癌安全性及可行性分析 　　[摘要] 目的 探讨分析肝癌切除术辅以DC-CIK细胞治疗原发性肝癌的安全性及可行性。 方法 该研究患者整群选自2012年2月―2013年2月收治的82例原发性肝癌患者，分为观察组和对照组，每组41例，分别给予两组患者肝癌切除术辅以DC/CIK细胞治疗和单纯肝癌切除术，对比两组治疗情况。 结果 两组治疗后生存率、生活质量改善情况等对比差异无统计学意义（P0.05）。观察组在DC-CIK治疗中有3例出现低烧且低温不超过38.5°，占7.31%，有1例出现轻度过敏反应，经对症治疗后均恢复正常。 结论 肝癌切除术辅以DC-CIK细胞治疗原发性肝癌能有效延长患者生存率，提高患者生活质量，安全性较高，值得临床推广和应用。 　　[关键词] 原发性肝癌；肝癌切除术；DC-CIK细胞；安全性 　　[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742（2016）04（a）-0076-02 　　[Abstract] Objective To discuss and analyze the safety and feasibility of hepatectomy for liver cancer supplemented by DC-CIK cells in treatment of primary liver cancer. Methods 82 cases of patients with primary liver cancer admitted and treated from February 2012 to February 2013 were selected and divided into two groups with 41 cases in each， the observation group were treated with hepatectomy for liver cancer supplemented by DC-CIK cells， the control group were treated with simple hepatectomy for liver cancer， and the treatment conditions were compared between the two groups. Results There was no significance in the survival rate and improvement of quality of life between the two groups after treatment， P0.05， the low fever and low temperature not more than 38.5°occurred to 3 cases， accounting for 7.31% in the observation group， mild anaphylactic reaction occurred to 1 case， and all were back to normal after symptomatic treatment. Conclusion The hepatectomy for liver cancer supplemented by DC-CIK cells in treatment of primary liver cancer can effectively prolong the survival time and improve the quality of life of patients with high safety， which is worth clinical promotion and application. 　　[Key words] Primary liver cancer； Hepatectomy for liver cancer； DC-CIK cells； Safety 　　原发性肝癌是我国常见的恶性肿瘤之一，男性多于女性，目前临床尚未确定该病的病因和发病机制，临床上治疗该病多采用肝癌切除术、肝脏移植等外科手术，其中肝癌切除术虽然是首选治疗，然而其术后复发率及疗效都欠佳，尤其患者术后免疫功能下降较易导致肿瘤转移、复发，因此在术后添加DC/CIK细胞治疗能清除患者体内微小病灶，提高免疫力[1-2]。肝癌切除术联合DC-CIK细胞治疗是否能延长肝癌患者生存时间，不同研究得出的结论也不尽相同。该院特整群选取2012年2月―2013年2月收治的82例原发性肝癌患者为研究对象在实施